Novartis increases sales of Genmab-developed sclerosis drug

On Wednesday, Novartis presented its full-year financial report, including sales figures for sclerosis drug Kesimpta, which was originally developed in Genmab’s labs.
Photo: CHARLES PLATIAU/Reuters / X00217
Photo: CHARLES PLATIAU/Reuters / X00217
by marketwire, translated by daniel pedersen

Genmab’s Swiss partner, Novartis, continues to push sales for sclerosis drug Kesimpta.

Already a subscriber?Log in here

Read the whole article

Get access for 14 days for free. No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

With your free trial you get:

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
  • Must be at least 8 characters, including three of: Uppercase, lowercase, numbers, symbols
    Must contain at least 2 characters
    Must contain at least 2 characters

    Get full access for you and your coworkers

    Start a free company trial today

    Share article

    Sign up for our newsletter

    Stay ahead of development by receiving our newsletter on the latest sector knowledge.

    Newsletter terms

    Front page now

    Further reading